Oxytocin Substitution Therapy in Patients With Central Diabetes Insipidus
Status:
Recruiting
Trial end date:
2026-10-01
Target enrollment:
Participant gender:
Summary
This randomized, placebo-controlled, double-blind trial aims to investigate intranasal OXT as
a novel therapeutical option in central diabetes insipidus (cDI) to improve psychological
symptoms and socio-emotional functioning.
Optionally, patients can present for additional assessments in sub-studies:
- fMRI sub-study at day 14 (± 2 days) (one additional visit)
- Social-stress sub-study at day 14 (± 2 days) (one additional visit)